Global Orphan Drugs for Adults Market 2023 by Company, Regions, Type and Application, Forecast to 2029
Page: 110
Published Date: 27 Jul 2023
Category: Medical Care
PDF Download
Get FREE Sample
Customize Request
- Description
- Table of Contents
- Table of Figures
- Research Methodology
- Companies Mentioned
- Related Reports
- Product Tags
Description
According to our (Global Info Research) latest study, the global Orphan Drugs for Adults market size was valued at USD 57280 million in 2022 and is forecast to a readjusted size of USD 105970 million by 2029 with a CAGR of 9.2% during review period.
Orphan drugs for adults refer to medications that are specifically developed and approved for the treatment of rare diseases or conditions in adult populations. These drugs are designed to address medical needs in adult patients who have limited treatment options due to the rarity of their conditions.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Orphan Drugs for Adults industry chain, the market status of Hospital Pharmacies (Oncology Drugs, Gastrointestinal Drugs), Retail pharmacies (Oncology Drugs, Gastrointestinal Drugs), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Orphan Drugs for Adults.
Regionally, the report analyzes the Orphan Drugs for Adults markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Orphan Drugs for Adults market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Orphan Drugs for Adults market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Orphan Drugs for Adults industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Oncology Drugs, Gastrointestinal Drugs).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Orphan Drugs for Adults market.
Regional Analysis: The report involves examining the Orphan Drugs for Adults market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Orphan Drugs for Adults market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Orphan Drugs for Adults:
Company Analysis: Report covers individual Orphan Drugs for Adults players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Orphan Drugs for Adults This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital Pharmacies, Retail pharmacies).
Technology Analysis: Report covers specific technologies relevant to Orphan Drugs for Adults. It assesses the current state, advancements, and potential future developments in Orphan Drugs for Adults areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Orphan Drugs for Adults market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Orphan Drugs for Adults market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others
Market segment by Application
Hospital Pharmacies
Retail pharmacies
Others
Market segment by players, this report covers
Abbvie
Orpharma
Amgen
Recordati
Novartis
Celgene
Amryt Pharma
Johnson & Johnson
GSK
Bristol-Myers Squibb Company
Roche Holding
Sanofi
Takeda
Pfizer
Vertex Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Orphan Drugs for Adults product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Orphan Drugs for Adults, with revenue, gross margin and global market share of Orphan Drugs for Adults from 2018 to 2023.
Chapter 3, the Orphan Drugs for Adults competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Orphan Drugs for Adults market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Orphan Drugs for Adults.
Chapter 13, to describe Orphan Drugs for Adults research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Orphan Drugs for Adults
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Orphan Drugs for Adults by Type
1.3.1 Overview: Global Orphan Drugs for Adults Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Orphan Drugs for Adults Consumption Value Market Share by Type in 2022
1.3.3 Oncology Drugs
1.3.4 Gastrointestinal Drugs
1.3.5 Neurology Drugs
1.3.6 Cardio-vascular Drugs
1.3.7 Others
1.4 Global Orphan Drugs for Adults Market by Application
1.4.1 Overview: Global Orphan Drugs for Adults Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacies
1.4.3 Retail pharmacies
1.4.4 Others
1.5 Global Orphan Drugs for Adults Market Size & Forecast
1.6 Global Orphan Drugs for Adults Market Size and Forecast by Region
1.6.1 Global Orphan Drugs for Adults Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Orphan Drugs for Adults Market Size by Region, (2018-2029)
1.6.3 North America Orphan Drugs for Adults Market Size and Prospect (2018-2029)
1.6.4 Europe Orphan Drugs for Adults Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Orphan Drugs for Adults Market Size and Prospect (2018-2029)
1.6.6 South America Orphan Drugs for Adults Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Orphan Drugs for Adults Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Abbvie
2.1.1 Abbvie Details
2.1.2 Abbvie Major Business
2.1.3 Abbvie Orphan Drugs for Adults Product and Solutions
2.1.4 Abbvie Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Abbvie Recent Developments and Future Plans
2.2 Orpharma
2.2.1 Orpharma Details
2.2.2 Orpharma Major Business
2.2.3 Orpharma Orphan Drugs for Adults Product and Solutions
2.2.4 Orpharma Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Orpharma Recent Developments and Future Plans
2.3 Amgen
2.3.1 Amgen Details
2.3.2 Amgen Major Business
2.3.3 Amgen Orphan Drugs for Adults Product and Solutions
2.3.4 Amgen Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Amgen Recent Developments and Future Plans
2.4 Recordati
2.4.1 Recordati Details
2.4.2 Recordati Major Business
2.4.3 Recordati Orphan Drugs for Adults Product and Solutions
2.4.4 Recordati Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Recordati Recent Developments and Future Plans
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business
2.5.3 Novartis Orphan Drugs for Adults Product and Solutions
2.5.4 Novartis Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Novartis Recent Developments and Future Plans
2.6 Celgene
2.6.1 Celgene Details
2.6.2 Celgene Major Business
2.6.3 Celgene Orphan Drugs for Adults Product and Solutions
2.6.4 Celgene Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Celgene Recent Developments and Future Plans
2.7 Amryt Pharma
2.7.1 Amryt Pharma Details
2.7.2 Amryt Pharma Major Business
2.7.3 Amryt Pharma Orphan Drugs for Adults Product and Solutions
2.7.4 Amryt Pharma Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Amryt Pharma Recent Developments and Future Plans
2.8 Johnson & Johnson
2.8.1 Johnson & Johnson Details
2.8.2 Johnson & Johnson Major Business
2.8.3 Johnson & Johnson Orphan Drugs for Adults Product and Solutions
2.8.4 Johnson & Johnson Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Johnson & Johnson Recent Developments and Future Plans
2.9 GSK
2.9.1 GSK Details
2.9.2 GSK Major Business
2.9.3 GSK Orphan Drugs for Adults Product and Solutions
2.9.4 GSK Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 GSK Recent Developments and Future Plans
2.10 Bristol-Myers Squibb Company
2.10.1 Bristol-Myers Squibb Company Details
2.10.2 Bristol-Myers Squibb Company Major Business
2.10.3 Bristol-Myers Squibb Company Orphan Drugs for Adults Product and Solutions
2.10.4 Bristol-Myers Squibb Company Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.11 Roche Holding
2.11.1 Roche Holding Details
2.11.2 Roche Holding Major Business
2.11.3 Roche Holding Orphan Drugs for Adults Product and Solutions
2.11.4 Roche Holding Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Roche Holding Recent Developments and Future Plans
2.12 Sanofi
2.12.1 Sanofi Details
2.12.2 Sanofi Major Business
2.12.3 Sanofi Orphan Drugs for Adults Product and Solutions
2.12.4 Sanofi Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Sanofi Recent Developments and Future Plans
2.13 Takeda
2.13.1 Takeda Details
2.13.2 Takeda Major Business
2.13.3 Takeda Orphan Drugs for Adults Product and Solutions
2.13.4 Takeda Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Takeda Recent Developments and Future Plans
2.14 Pfizer
2.14.1 Pfizer Details
2.14.2 Pfizer Major Business
2.14.3 Pfizer Orphan Drugs for Adults Product and Solutions
2.14.4 Pfizer Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Pfizer Recent Developments and Future Plans
2.15 Vertex Pharmaceuticals
2.15.1 Vertex Pharmaceuticals Details
2.15.2 Vertex Pharmaceuticals Major Business
2.15.3 Vertex Pharmaceuticals Orphan Drugs for Adults Product and Solutions
2.15.4 Vertex Pharmaceuticals Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Vertex Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Orphan Drugs for Adults Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Orphan Drugs for Adults by Company Revenue
3.2.2 Top 3 Orphan Drugs for Adults Players Market Share in 2022
3.2.3 Top 6 Orphan Drugs for Adults Players Market Share in 2022
3.3 Orphan Drugs for Adults Market: Overall Company Footprint Analysis
3.3.1 Orphan Drugs for Adults Market: Region Footprint
3.3.2 Orphan Drugs for Adults Market: Company Product Type Footprint
3.3.3 Orphan Drugs for Adults Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Orphan Drugs for Adults Consumption Value and Market Share by Type (2018-2023)
4.2 Global Orphan Drugs for Adults Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Orphan Drugs for Adults Consumption Value Market Share by Application (2018-2023)
5.2 Global Orphan Drugs for Adults Market Forecast by Application (2024-2029)
6 North America
6.1 North America Orphan Drugs for Adults Consumption Value by Type (2018-2029)
6.2 North America Orphan Drugs for Adults Consumption Value by Application (2018-2029)
6.3 North America Orphan Drugs for Adults Market Size by Country
6.3.1 North America Orphan Drugs for Adults Consumption Value by Country (2018-2029)
6.3.2 United States Orphan Drugs for Adults Market Size and Forecast (2018-2029)
6.3.3 Canada Orphan Drugs for Adults Market Size and Forecast (2018-2029)
6.3.4 Mexico Orphan Drugs for Adults Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Orphan Drugs for Adults Consumption Value by Type (2018-2029)
7.2 Europe Orphan Drugs for Adults Consumption Value by Application (2018-2029)
7.3 Europe Orphan Drugs for Adults Market Size by Country
7.3.1 Europe Orphan Drugs for Adults Consumption Value by Country (2018-2029)
7.3.2 Germany Orphan Drugs for Adults Market Size and Forecast (2018-2029)
7.3.3 France Orphan Drugs for Adults Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Orphan Drugs for Adults Market Size and Forecast (2018-2029)
7.3.5 Russia Orphan Drugs for Adults Market Size and Forecast (2018-2029)
7.3.6 Italy Orphan Drugs for Adults Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Orphan Drugs for Adults Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Orphan Drugs for Adults Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Orphan Drugs for Adults Market Size by Region
8.3.1 Asia-Pacific Orphan Drugs for Adults Consumption Value by Region (2018-2029)
8.3.2 China Orphan Drugs for Adults Market Size and Forecast (2018-2029)
8.3.3 Japan Orphan Drugs for Adults Market Size and Forecast (2018-2029)
8.3.4 South Korea Orphan Drugs for Adults Market Size and Forecast (2018-2029)
8.3.5 India Orphan Drugs for Adults Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Orphan Drugs for Adults Market Size and Forecast (2018-2029)
8.3.7 Australia Orphan Drugs for Adults Market Size and Forecast (2018-2029)
9 South America
9.1 South America Orphan Drugs for Adults Consumption Value by Type (2018-2029)
9.2 South America Orphan Drugs for Adults Consumption Value by Application (2018-2029)
9.3 South America Orphan Drugs for Adults Market Size by Country
9.3.1 South America Orphan Drugs for Adults Consumption Value by Country (2018-2029)
9.3.2 Brazil Orphan Drugs for Adults Market Size and Forecast (2018-2029)
9.3.3 Argentina Orphan Drugs for Adults Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Orphan Drugs for Adults Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Orphan Drugs for Adults Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Orphan Drugs for Adults Market Size by Country
10.3.1 Middle East & Africa Orphan Drugs for Adults Consumption Value by Country (2018-2029)
10.3.2 Turkey Orphan Drugs for Adults Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Orphan Drugs for Adults Market Size and Forecast (2018-2029)
10.3.4 UAE Orphan Drugs for Adults Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Orphan Drugs for Adults Market Drivers
11.2 Orphan Drugs for Adults Market Restraints
11.3 Orphan Drugs for Adults Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Orphan Drugs for Adults Industry Chain
12.2 Orphan Drugs for Adults Upstream Analysis
12.3 Orphan Drugs for Adults Midstream Analysis
12.4 Orphan Drugs for Adults Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Orphan Drugs for Adults Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Orphan Drugs for Adults Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Orphan Drugs for Adults Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Orphan Drugs for Adults Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Abbvie Company Information, Head Office, and Major Competitors
Table 6. Abbvie Major Business
Table 7. Abbvie Orphan Drugs for Adults Product and Solutions
Table 8. Abbvie Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Abbvie Recent Developments and Future Plans
Table 10. Orpharma Company Information, Head Office, and Major Competitors
Table 11. Orpharma Major Business
Table 12. Orpharma Orphan Drugs for Adults Product and Solutions
Table 13. Orpharma Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Orpharma Recent Developments and Future Plans
Table 15. Amgen Company Information, Head Office, and Major Competitors
Table 16. Amgen Major Business
Table 17. Amgen Orphan Drugs for Adults Product and Solutions
Table 18. Amgen Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Amgen Recent Developments and Future Plans
Table 20. Recordati Company Information, Head Office, and Major Competitors
Table 21. Recordati Major Business
Table 22. Recordati Orphan Drugs for Adults Product and Solutions
Table 23. Recordati Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Recordati Recent Developments and Future Plans
Table 25. Novartis Company Information, Head Office, and Major Competitors
Table 26. Novartis Major Business
Table 27. Novartis Orphan Drugs for Adults Product and Solutions
Table 28. Novartis Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Novartis Recent Developments and Future Plans
Table 30. Celgene Company Information, Head Office, and Major Competitors
Table 31. Celgene Major Business
Table 32. Celgene Orphan Drugs for Adults Product and Solutions
Table 33. Celgene Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Celgene Recent Developments and Future Plans
Table 35. Amryt Pharma Company Information, Head Office, and Major Competitors
Table 36. Amryt Pharma Major Business
Table 37. Amryt Pharma Orphan Drugs for Adults Product and Solutions
Table 38. Amryt Pharma Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Amryt Pharma Recent Developments and Future Plans
Table 40. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 41. Johnson & Johnson Major Business
Table 42. Johnson & Johnson Orphan Drugs for Adults Product and Solutions
Table 43. Johnson & Johnson Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Johnson & Johnson Recent Developments and Future Plans
Table 45. GSK Company Information, Head Office, and Major Competitors
Table 46. GSK Major Business
Table 47. GSK Orphan Drugs for Adults Product and Solutions
Table 48. GSK Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. GSK Recent Developments and Future Plans
Table 50. Bristol-Myers Squibb Company Company Information, Head Office, and Major Competitors
Table 51. Bristol-Myers Squibb Company Major Business
Table 52. Bristol-Myers Squibb Company Orphan Drugs for Adults Product and Solutions
Table 53. Bristol-Myers Squibb Company Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Bristol-Myers Squibb Company Recent Developments and Future Plans
Table 55. Roche Holding Company Information, Head Office, and Major Competitors
Table 56. Roche Holding Major Business
Table 57. Roche Holding Orphan Drugs for Adults Product and Solutions
Table 58. Roche Holding Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Roche Holding Recent Developments and Future Plans
Table 60. Sanofi Company Information, Head Office, and Major Competitors
Table 61. Sanofi Major Business
Table 62. Sanofi Orphan Drugs for Adults Product and Solutions
Table 63. Sanofi Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Sanofi Recent Developments and Future Plans
Table 65. Takeda Company Information, Head Office, and Major Competitors
Table 66. Takeda Major Business
Table 67. Takeda Orphan Drugs for Adults Product and Solutions
Table 68. Takeda Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Takeda Recent Developments and Future Plans
Table 70. Pfizer Company Information, Head Office, and Major Competitors
Table 71. Pfizer Major Business
Table 72. Pfizer Orphan Drugs for Adults Product and Solutions
Table 73. Pfizer Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Pfizer Recent Developments and Future Plans
Table 75. Vertex Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 76. Vertex Pharmaceuticals Major Business
Table 77. Vertex Pharmaceuticals Orphan Drugs for Adults Product and Solutions
Table 78. Vertex Pharmaceuticals Orphan Drugs for Adults Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Vertex Pharmaceuticals Recent Developments and Future Plans
Table 80. Global Orphan Drugs for Adults Revenue (USD Million) by Players (2018-2023)
Table 81. Global Orphan Drugs for Adults Revenue Share by Players (2018-2023)
Table 82. Breakdown of Orphan Drugs for Adults by Company Type (Tier 1, Tier 2, and Tier 3)
Table 83. Market Position of Players in Orphan Drugs for Adults, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 84. Head Office of Key Orphan Drugs for Adults Players
Table 85. Orphan Drugs for Adults Market: Company Product Type Footprint
Table 86. Orphan Drugs for Adults Market: Company Product Application Footprint
Table 87. Orphan Drugs for Adults New Market Entrants and Barriers to Market Entry
Table 88. Orphan Drugs for Adults Mergers, Acquisition, Agreements, and Collaborations
Table 89. Global Orphan Drugs for Adults Consumption Value (USD Million) by Type (2018-2023)
Table 90. Global Orphan Drugs for Adults Consumption Value Share by Type (2018-2023)
Table 91. Global Orphan Drugs for Adults Consumption Value Forecast by Type (2024-2029)
Table 92. Global Orphan Drugs for Adults Consumption Value by Application (2018-2023)
Table 93. Global Orphan Drugs for Adults Consumption Value Forecast by Application (2024-2029)
Table 94. North America Orphan Drugs for Adults Consumption Value by Type (2018-2023) & (USD Million)
Table 95. North America Orphan Drugs for Adults Consumption Value by Type (2024-2029) & (USD Million)
Table 96. North America Orphan Drugs for Adults Consumption Value by Application (2018-2023) & (USD Million)
Table 97. North America Orphan Drugs for Adults Consumption Value by Application (2024-2029) & (USD Million)
Table 98. North America Orphan Drugs for Adults Consumption Value by Country (2018-2023) & (USD Million)
Table 99. North America Orphan Drugs for Adults Consumption Value by Country (2024-2029) & (USD Million)
Table 100. Europe Orphan Drugs for Adults Consumption Value by Type (2018-2023) & (USD Million)
Table 101. Europe Orphan Drugs for Adults Consumption Value by Type (2024-2029) & (USD Million)
Table 102. Europe Orphan Drugs for Adults Consumption Value by Application (2018-2023) & (USD Million)
Table 103. Europe Orphan Drugs for Adults Consumption Value by Application (2024-2029) & (USD Million)
Table 104. Europe Orphan Drugs for Adults Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Orphan Drugs for Adults Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Orphan Drugs for Adults Consumption Value by Type (2018-2023) & (USD Million)
Table 107. Asia-Pacific Orphan Drugs for Adults Consumption Value by Type (2024-2029) & (USD Million)
Table 108. Asia-Pacific Orphan Drugs for Adults Consumption Value by Application (2018-2023) & (USD Million)
Table 109. Asia-Pacific Orphan Drugs for Adults Consumption Value by Application (2024-2029) & (USD Million)
Table 110. Asia-Pacific Orphan Drugs for Adults Consumption Value by Region (2018-2023) & (USD Million)
Table 111. Asia-Pacific Orphan Drugs for Adults Consumption Value by Region (2024-2029) & (USD Million)
Table 112. South America Orphan Drugs for Adults Consumption Value by Type (2018-2023) & (USD Million)
Table 113. South America Orphan Drugs for Adults Consumption Value by Type (2024-2029) & (USD Million)
Table 114. South America Orphan Drugs for Adults Consumption Value by Application (2018-2023) & (USD Million)
Table 115. South America Orphan Drugs for Adults Consumption Value by Application (2024-2029) & (USD Million)
Table 116. South America Orphan Drugs for Adults Consumption Value by Country (2018-2023) & (USD Million)
Table 117. South America Orphan Drugs for Adults Consumption Value by Country (2024-2029) & (USD Million)
Table 118. Middle East & Africa Orphan Drugs for Adults Consumption Value by Type (2018-2023) & (USD Million)
Table 119. Middle East & Africa Orphan Drugs for Adults Consumption Value by Type (2024-2029) & (USD Million)
Table 120. Middle East & Africa Orphan Drugs for Adults Consumption Value by Application (2018-2023) & (USD Million)
Table 121. Middle East & Africa Orphan Drugs for Adults Consumption Value by Application (2024-2029) & (USD Million)
Table 122. Middle East & Africa Orphan Drugs for Adults Consumption Value by Country (2018-2023) & (USD Million)
Table 123. Middle East & Africa Orphan Drugs for Adults Consumption Value by Country (2024-2029) & (USD Million)
Table 124. Orphan Drugs for Adults Raw Material
Table 125. Key Suppliers of Orphan Drugs for Adults Raw Materials
List of Figures
Figure 1. Orphan Drugs for Adults Picture
Figure 2. Global Orphan Drugs for Adults Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Orphan Drugs for Adults Consumption Value Market Share by Type in 2022
Figure 4. Oncology Drugs
Figure 5. Gastrointestinal Drugs
Figure 6. Neurology Drugs
Figure 7. Cardio-vascular Drugs
Figure 8. Others
Figure 9. Global Orphan Drugs for Adults Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 10. Orphan Drugs for Adults Consumption Value Market Share by Application in 2022
Figure 11. Hospital Pharmacies Picture
Figure 12. Retail pharmacies Picture
Figure 13. Others Picture
Figure 14. Global Orphan Drugs for Adults Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Orphan Drugs for Adults Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Orphan Drugs for Adults Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Orphan Drugs for Adults Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Orphan Drugs for Adults Consumption Value Market Share by Region in 2022
Figure 19. North America Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Orphan Drugs for Adults Revenue Share by Players in 2022
Figure 25. Orphan Drugs for Adults Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Orphan Drugs for Adults Market Share in 2022
Figure 27. Global Top 6 Players Orphan Drugs for Adults Market Share in 2022
Figure 28. Global Orphan Drugs for Adults Consumption Value Share by Type (2018-2023)
Figure 29. Global Orphan Drugs for Adults Market Share Forecast by Type (2024-2029)
Figure 30. Global Orphan Drugs for Adults Consumption Value Share by Application (2018-2023)
Figure 31. Global Orphan Drugs for Adults Market Share Forecast by Application (2024-2029)
Figure 32. North America Orphan Drugs for Adults Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Orphan Drugs for Adults Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Orphan Drugs for Adults Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Orphan Drugs for Adults Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Orphan Drugs for Adults Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Orphan Drugs for Adults Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 42. France Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Orphan Drugs for Adults Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Orphan Drugs for Adults Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Orphan Drugs for Adults Consumption Value Market Share by Region (2018-2029)
Figure 49. China Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 52. India Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Orphan Drugs for Adults Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Orphan Drugs for Adults Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Orphan Drugs for Adults Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Orphan Drugs for Adults Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Orphan Drugs for Adults Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Orphan Drugs for Adults Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Orphan Drugs for Adults Consumption Value (2018-2029) & (USD Million)
Figure 66. Orphan Drugs for Adults Market Drivers
Figure 67. Orphan Drugs for Adults Market Restraints
Figure 68. Orphan Drugs for Adults Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Orphan Drugs for Adults in 2022
Figure 71. Manufacturing Process Analysis of Orphan Drugs for Adults
Figure 72. Orphan Drugs for Adults Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Abbvie Orpharma Amgen Recordati Novartis Celgene Amryt Pharma Johnson & Johnson GSK Bristol-Myers Squibb Company Roche Holding Sanofi Takeda Pfizer Vertex Pharmaceuticals
Related Reports
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
-
Insight into the industry market information
-
Analyze market development needs
-
Prospects for future development
-
Develop industry investment strategy
-
- Digging deeper into global industry information and providing market strategies.Contact Us >>